Organization Overview
Historical Acquisition Tree
Alternative names
adalimumab (humira) (2021)
filgrastim (neupogen) (2018)
Arthritis (Phase 3)
Arthritis, Rheumatoid (Phase 3)
Multiple Sclerosis (Phase 2)
Multiple Sclerosis, Relapsing-Remitting (Phase 2)
Psoriasis (Phase 3)
Sclerosis (Phase 2)